Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

Disclosed are an anticancer prodrug nucleoside cyclic phosphate compound based on liver-specific delivery (LSD) technology and the use thereof, in particular, provided are a compound of formula (I) and an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate and a corresponding pharmaceutical composition thereof, and the use of the compound alone or in combination with other anticancer drugs against cancer, especially in treating hepatic carcinoma (HCC). ##STR00001##

The present disclosure provides an electrolyte and an electrochemical energy storage device, the electrolyte comprises an electrolyte salt and an additive. The additive comprises a sulfonic ester cyclic quaternary ammonium salt and a multinitrile compound. The sulfonic ester cyclic quaternary ammonium salt and the multinitrile compound can form a dense and uniform passive film with high ionic conductivity on a surface of each of the positive electrode film and the negative electrode film, so as to prevent continuous oxidation and reduction reaction from occurring between the electrolyte and the positive electrode film and the negative electrode film and make the electrochemical energy storage device has excellent high temperature cycle performance and high temperature storage performance.

The present invention relates to a lithium secondary battery comprising: a negative electrode comprising a negative electrode active material containing Si or Sn, a positive electrode comprising a positive electrode active material, and a non-aqueous electrolyte. The non-aqueous electrolyte comprises: a non-aqueous organic solvent; a lithium salt; fluoroethylene carbonate; a first additive containing at least one compound among compounds resented by chemical formulas 1 to 4; and a second additive containing at least one compound among compounds represented by chemical formula 5 or 6.

Provided herein are organophosphates and pharmaceutical compositions comprising said compounds.

The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Disclosed is a liver specific delivery (LSD)-based entecavir antiviral prodrug, i.e., a nucleoside cyclic phosphate compound, and the application thereof. Specifically, disclosed are a compound as represented by formula (I) and isomers, pharmaceutically acceptable salts, hydrates, and solvates of the compound, and a corresponding pharmaceutical composition. Also disclosed is the application of the compound of the present invention, used separately or used in combination with other antiviral drugs, against viruses, especially the application against hepatitis B virus (HBV).

##STR00001##

Disclosed are an anticancer prodrug nucleoside cyclic phosphate compound based on liver-specific delivery (LSD) technology and the use thereof, in particular, provided are a compound of formula (I) and an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate and a corresponding pharmaceutical composition thereof, and the use of the compound alone or in combination with other anticancer drugs against cancer, especially in treating hepatic carcinoma (HCC).

##STR00001##

Provided are a liver specific delivery (LSD)-based anticancer prodrug nucleoside cyclic phosphate compound and an application thereof, and in particular, a compound represented by formula (I) as well as isomers, pharmaceutically acceptable salts, hydrates, and solvates thereof, and corresponding pharmaceutical compositions. Also provided is an application of the compound alone or in combination with other anticancer drugs in anticancer area, particularly the treatment of hepatocellular carcinoma (HHC).

##STR00001##